2024 - 2032 年非鸦片类止痛贴市场机会、成长动力、产业趋势分析与预测

Non-opioid Pain Patch Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年10月24日 | 出版商:

Global Market Insights Inc. | 英文 135 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023年，全球非鸦片类止痛贴片市场规模达8.283亿美元，预计2024年至2032年复合年增长率为6.6%。提供有针对性的疼痛缓解，而没有与鸦片类药物相关的风险。这些贴片可有效治疗慢性、神经性、肌肉骨骼和术后疼痛，提供鸦片类药物的安全替代品，满足对非成瘾性、有效疼痛管理解决方案的需求。疼痛管理的研究和开发不断增加，包括 NIH Heal Initiative 等倡议，该计划的重点是推动慢性疼痛治疗并减少阿片类药物使用障碍 (OUD) 和用药过量率，从而推动了市场的发展。此类计画正在促进开发更安全、不含鸦片类药物的治疗方法，从而显着增加对非鸦片类止痛贴的需求。

从产品来看，市场包括利多卡因、双氯芬酸、水杨酸甲酯、辣椒素、酮洛芬和其他止痛贴片。利多卡因细分市场在 2023 年以 3.57 亿美元的收入引领市场，由于人们对阿片类替代品的兴趣不断增加，显示出强劲的成长潜力。与鸦片类药物相关的高成瘾率和死亡率促使医疗保健提供者和患者转向更安全的选择，例如利多卡因贴片，它可以缓解局部疼痛，而没有成瘾风险。在治疗应用方面，慢性疼痛管理领域的非鸦片类止痛贴片市场在 2023 年占据 42.4% 的市场份额，预计将显着成长。

非鸦片类药物贴片已被证明可以有效控制慢性疼痛，通常与口服药物相当，并且具有持续、局部缓解的额外优势。临床研究强调了它们的实用性，促使更多人采用长期疼痛管理。美国主导市场，2023 年营收为 2.443 亿美元，预计将出现强劲成长。政府对阿片类药物处方的监管，包括 FDA 提倡非阿片类药物选择的指南，刺激了对含有利多卡因、双氯芬酸和辣椒素的止痛贴片的需求，用于治疗慢性和急性疼痛。

市场范围
开始年份	2023年
预测年份	2024-2032
起始值	8.283 亿美元
预测值	15亿美元
复合年增长率	6.6%

此外，美国老年人口不断增加，肌肉骨骼疾病、慢性关节疼痛和关节炎的发生率更高，这进一步推动了对非鸦片类疼痛管理解决方案的需求。

产业生态系统分析
产业影响力
- 成长动力
  - 阿片类药物处方的使用越来越多
  - 疼痛相关疾病的发生率上升
  - 与其他形式的药物相比，非鸦片类止痛贴片具有优势
  - 疼痛管理治疗的研发不断增加
- 产业陷阱与挑战
  - 长期使用非鸦片类止痛贴片所引起的副作用
  - 替代治疗的可用性
成长潜力分析
监管环境
- 我们
- 欧洲
技术景观
- 核心技术
- 邻近技术
报销场景
定价分析
- 按地区
- 副产品
消费者行为分析
未来市场趋势
专利分析
利润率分析
管道分析
临床试验情况
差距分析
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按产品类型，2021 - 2032

主要趋势
利多卡因贴剂
双氯芬酸贴剂
水杨酸甲酯贴片
辣椒素贴片
酮洛芬贴剂
其他补丁

第 6 章：市场估计与预测：按治疗应用分类，2021 - 2032 年

主要趋势
慢性疼痛
急性疼痛
神经性疼痛
肌肉骨骼疼痛
其他治疗应用

第 7 章：市场估计与预测：按配销通路，2021 - 2032 年

主要趋势
医院药房
零售药局
网路药局

第 8 章：市场估计与预测：按地区划分，2021 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋

第 9 章：公司简介

Acorda Therapeutics
AdhexPharma
Endo Pharmaceuticals
Glaxo SmithKline
Grunenthal
Hisamitsu Pharmaceutical
IBSA Institut Biochimique
Johnson & Johnson
Mylan (Viatris)
Nichiban
Pfizer
ProSolus
Sanofi
Teikoku Seiyaku
Teva Pharmaceuticals

简介目录

Product Code: 11974

The Global Non-opioid Pain Patch Market reached USD 828.3 million in 2023 and is projected to grow at a CAGR of 6.6% from 2024 to 2032. Non-opioid pain patches are transdermic devices designed to deliver medication directly through the skin, providing targeted pain relief without the risks associated with opioids. Effective in managing chronic, neuropathic, musculoskeletal, and post-surgical pain, these patches offer a safe alternative to opioid medications, addressing the need for non-addictive, effective pain management solutions. The market is propelled by increasing research and development in pain management, including initiatives like the NIH Heal Initiative, which focuses on advancing chronic pain treatment and reducing opioid use disorder (OUD) and overdose rates. Such programs are fostering the development of safer, opioid-free treatments, significantly boosting the demand for non-opioid pain patches.

Product-wise, the market includes lidocaine, diclofenac, methyl salicylate, capsaicin, ketoprofen, and other pain-relief patches. The lidocaine segment led the market in 2023 with revenues of USD 357 million, showing strong growth potential due to the escalating interest in opioid alternatives. The high rates of addiction and fatalities linked to opioid medications have pushed healthcare providers and patients toward safer options like lidocaine patches, which deliver localized pain relief without addiction risks. Regarding therapeutic application, the non-opioid pain patch market from the Chronic pain management held a significant 42.4% market share in 2023 and is expected to see notable growth.

Non-opioid patches have proven effective in managing chronic pain, often comparable to oral medications, with the added advantage of continuous, localized relief. Clinical studies underscore their utility, prompting greater adoption for long-term pain management. U.S. dominated the market, generating USD 244.3 million in revenue in 2023, and is anticipated to experience strong growth. Government regulations on opioid prescriptions, including FDA guidelines promoting non-opioid options, have fueled demand for pain patches containing lidocaine, diclofenac, and capsaicin for both chronic and acute pain.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$828.3 Million
Forecast Value	$1.5 Billion
CAGR	6.6%

Additionally, the U.S. has a growing elderly population, which experiences higher rates of musculoskeletal conditions, chronic joint pain, and arthritis-further driving the need for non-opioid pain management solutions.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing use of opioid prescriptions
  - 3.2.1.2 Rising incidence of pain related disorders
  - 3.2.1.3 Advantages offered by non-opioid pain patches over other forms of medications
  - 3.2.1.4 Rising R&D in pain management treatments
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Side effects caused by prolonged use of non-opioid pain patches
  - 3.2.2.2 Availability of alternative treatments
3.3 Growth potential analysis
3.4 Regulatory landscape
- 3.4.1 U.S.
- 3.4.2 Europe
3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
3.6 Reimbursement scenario
3.7 Pricing analysis
- 3.7.1 By region
- 3.7.2 By product
3.8 Consumer behavior analysis
3.9 Future market trends
3.10 Patent analysis
3.11 Profit margin analysis
3.12 Pipeline analysis
3.13 Clinical trial landscape
3.14 Gap analysis
3.15 Porter's analysis
3.16 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Lidocaine patches
5.3 Diclofenac patches
5.4 Methyl Salicylate patches
5.5 Capsaicin patches
5.6 Ketoprofen patches
5.7 Other patches

Chapter 6 Market Estimates and Forecast, By Therapeutic Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Chronic pain
6.3 Acute pain
6.4 Neuropathic pain
6.5 Musculoskeletal pain
6.6 Other therapeutic applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE